| Dronedarone for atrial fibrillation? | |
| | |
MedLine Citation:
|
PMID: 21057032 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
Atrial fibrillation (AF) is the commonest sustained heart arrhythmia and is associated with significant morbidity and mortality, with, for example, one in five of all strokes being attributable to the condition. Dronedarone (pronounced dro-ne-da-roan) (Multaq--sanofi-aventis) is a new anti-arrhythmic drug related to the established anti-arrhythmic amiodarone. It is licensed for use in clinically stable adult patients with a history of, or current, non-permanent AF to prevent recurrence of AF or to lower ventricular rate. Here we review its role in the management of patients with non-permanent AF. |
| | |
Authors:
|
- |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Drug and therapeutics bulletin Volume: 48 ISSN: 0012-6543 ISO Abbreviation: Drug Ther Bull Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-08 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0112037 Medline TA: Drug Ther Bull Country: England |
Other Details:
|
Languages: eng Pagination: 126-8 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Seasonal flu vaccination for healthcare workers?
Next Document: Artemisinins in malaria treatment in the UK.